ProCE Banner Activity

ExteNET: DFS With Neratinib in HER2+ BC After Adjuvant Trastuzumab

Slideset Download
Conference Coverage
Greatest benefit seen in those with centrally confirmed HER2+ disease, completion of trastuzumab within 1 year of study entry, and hormone receptor–positive disease.

Released: December 14, 2015

Expiration: December 12, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation